%D9%81%D9%8A%D8%A8%D9%88%D9%83%D8%B3%D9%88%D8%B3%D8%AA%D8%A7%D8%AACategory:FebuxostatFebuxostatFebuxostatFebuxostatFebuxostatFebuksostatFebuxostat%E3%83%95%E3%82%A7%E3%83%96%E3%82%AD%E3%82%BD%E3%82%B9%E3%82%BF%E3%83%83%E3%83%88%E0%AC%AB%E0%AD%87%E0%AC%AC%E0%AD%81%E0%AC%95%E0%AD%8D%E0%AC%B8%E0%AD%8B%E0%AC%B8%E0%AD%8D%E0%AC%9F%E0%AC%BE%E0%AC%9FFebuksostatFebuksostatFebuksostatQ417296
about
sameAs
P2176
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal ImpairmentFebuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and AdultsCardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate StonesStudy of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood PressureCombination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and FebuxostatEffect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney Injury (CI-AKI)Febuxostat Versus Allopurinol Control Trial in Subjects With GoutUrate Lowering Therapies and Left Ventricular Diastolic DysfunctionClinical Study to Evaluate the Pharmacokinetic Characteristics Between TMX-67 and Feburic® in Healthy VolunteersEffect of Febuxostat on Blood PressureOpen Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout PatientsEffects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney DiseaseFebuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)Effect of Hyperuricaemia on Chronic Renal DiseaseUric Acid Effects on Endothelium and Oxydative StressA Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With HyperuricemiaA Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UAThe Study is Designed to Evaluate Single Ascending Doses of AR882 in Healthy Adult MalesRole of Uralyt-U in Patients With HyperuricemiaA Randomized Clinical Trail of The Effect of Postoperative Uric Acid Control on Stone Recurrence and Renal Function in Patients With Hyperuricemia of Urolithiasis.
P4844
Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout.Bioequivalence Study of Two Formulations of Febuxostat 120 mg Film-coated Tablets in Healthy Adult Volunteers After a Single Oral Dose Administration Under Fasting ConditionsSafety and Efficacy of Oral Febuxostat in Subjects With GoutThe Blood Pressure Effects of Febuxostat in Patients Previously Treated With Allopurinol: A Pilot StudyFebuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy.Gout: Allopurinol vs. FebuxostatIntensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With GoutThe Effect of Uric Acid Lowering in Type 1 DiabetesCompare the Renal Protective Effects of Febuxostat and BenzbromaroneThe Cardiovascular Protective Effects of Febuxostat in Peritoneal Dialysis PatientsCompare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese PatientsZurig (Febuxostat) 40mg Efficacy and Safety TrialEfficacy and Safety of Simiaowan in Prevention of Acute Flares in Chronic Gout Patients Initiating Febuxostat TherapyThe Influence of Urate-lowering Therapy on Sperm Quality of Male Gouty Patients:A Prospective Cohort StudyA Randomized, Double-Blind, Non-Inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects With or Without GoutInhibition of xanthine oxidoreductase protects against contrast-induced renal tubular injury by activating adenosine monophosphate-activated protein kinaseSwitching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipientsFreeze-Dried Self-Nanoemulsifying Self-Nanosuspension (SNESNS): a New Approach for the Preparation of a Highly Drug-Loaded Dosage FormEffects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysisThe net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysisComparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: a propensity-matched analysis of Medicare claims dataEffects of febuxostat on atrial remodeling in a rabbit model of atrial fibrillation induced by rapid atrial pacingThe impact of adoption of a new urate-lowering agent on trends in utilization and cost in practiceFebuxostat attenuates ulcerative colitis by the inhibition of NF-κB, proinflammatory cytokines, and oxidative stress in mice
P921
Q61894552-437F450D-0DA6-4314-B91A-DCA1D9437F54Q61907330-D7988D7B-91F0-4115-AA5C-827E939EE448Q61936051-7C19276E-5EA4-4B91-8A26-5C3D260D5A41Q61938043-7B6B0875-40CD-4E7B-B721-E995867DA5A9Q61955424-D6F3AC87-C62E-4AFB-A709-CEFDCE178665Q61956138-08CC7588-D94F-4EF5-AE9D-A493777557F5Q62031639-10887375-83B1-485D-8BD5-2F1D9B663007Q62106265-1C172700-FF37-4005-B69A-B08DF612A846Q62815070-B8514B5A-7E32-4E52-9C10-A4962F19C617Q63316008-3405C3C9-85A7-4212-A906-5D09D043ED9CQ63319101-267CFC04-3A49-403D-9BAB-C166BD67FAC9Q63322868-3B0CC09A-B14D-447D-AD52-5B494842D022Q63334830-0E60A7AF-C9B9-4D95-BCB7-F8A1C7D26D91Q63338447-734F9850-3C30-4D23-B4CA-3452264A1BBBQ63401717-6FA30FFB-F083-408A-B0D8-7E40A1ABF8E6Q63403715-A1DEE27E-AC3A-49BF-AC86-E09E5CD77E2FQ63805552-A7158016-CA34-4984-9832-FE4DBBB4A25AQ63811368-2E683A6B-9DF0-482B-9C1F-2EB8FA9ECAACQ92207864-EF126063-E96E-40C3-B5D9-13CE8DAA8327Q92273624-AEA0B77B-FBEA-462C-8C76-F2B528690D52Q95056320-52D47BC8-A1C6-4ABF-8BD8-336E51F71416
P4844
Q38365938-971104B3-CF8D-4F18-AD38-A5611DD6D498Q64139892-4E75F7D4-8179-4494-A7B8-3B25F8192893Q64221676-061BD25E-A501-454F-B4B4-EE63E9D35917Q64640394-F83A850E-DB70-40C3-96E1-43F549830B43Q64997372-33BF2587-F88D-4BFF-B27B-0917B72392B4Q65316390-6B54C1D9-1923-42B4-8630-319731D2E30AQ65342669-502A6E58-EFE5-401B-BA9E-04137D0A05A2Q65348789-FA85954F-6E5F-4C8B-9C20-75E2F30AAF70Q65349803-806B16D4-70B0-4FBC-A46F-02C19E424225Q65349852-04204E9B-CD62-4C67-93F8-1210835B5DC5Q66079622-A01E5FFB-4562-4503-9B97-C3AEB238D0E6Q67126594-B9CE37E5-E2CD-4A12-BBFC-D88ACCC74B86Q74287330-3C61A55D-91F0-4557-9DB4-32309274B54DQ83793931-6A8FCB14-C09F-4924-B1D6-35AABDBFF6C9Q90156318-99DCDAE1-0F21-418E-BF49-3838192697AEQ90331149-4A4EF442-6A2E-43E1-BD3A-6DB3F5B32C81Q91571724-97C4D027-ADC6-44C5-B49E-9393B2CFC226Q92096802-A21C91BF-B259-45C6-8A46-D3A9207EF50EQ92120306-CC0D61BE-2D37-4105-B8ED-2D990D745BF9Q92396624-6CEBDA62-5CBE-477B-9A85-62A9135BAE53Q92668144-504C238F-DEC5-40B9-81F1-E171F9D78F21Q92858040-367B1736-BF2D-45A1-BDDB-BE652F30EAAFQ92867424-AD36B7B7-14A7-4ECA-87B5-5DD69DAABD03Q93198555-1BAAB98B-BBE1-4F69-81F8-C327A43892EC
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische Verbindung, Arzneistoff
@de
chemische verbinding
@nl
name
Febuksostat
@id
Febuksostat
@sh
Febuksostat
@sr
Febuxostat
@de
Febuxostat
@es
Febuxostat
@it
Febuxostat
@vi
febuksostat
@pl
febuxostat
@en
febuxostat
@fr
type
label
Febuksostat
@id
Febuksostat
@sh
Febuksostat
@sr
Febuxostat
@de
Febuxostat
@es
Febuxostat
@it
Febuxostat
@vi
febuksostat
@pl
febuxostat
@en
febuxostat
@fr
altLabel
144060-53-7
@fr
2-(3-cyano-4-isobutoxyphenyl)-4-methyl- 1,3-thiazole-5-carboxylic acid
@en
Adenuric
@de
Adenuric
@es
Adenuric®
@en
C16H16N2O3S
@fr
Febuxostat
@en
Febuxostatum
@en
Fébuxostat
@en
MX-67
@en
prefLabel
Febuksostat
@id
Febuksostat
@sh
Febuksostat
@sr
Febuxostat
@de
Febuxostat
@es
Febuxostat
@it
Febuxostat
@vi
febuksostat
@pl
febuxostat
@en
febuxostat
@fr